Pfiz­er re-ups on Mis­sion Ther­a­peu­tics col­lab­o­ra­tion, lead­ing a $15M round and grab­bing first dibs on DUBs

Sev­en years af­ter Pfiz­er first in­vest­ed in Mis­sion Ther­a­peu­tics, a biotech that re­search­es se­lec­tive­ly in­hibit­ing deu­biq­ui­ty­lat­ing en­zymes (DUBs), the phar­ma gi­ant is re-up­ping its com­mit­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER